Skip to main content
Article thumbnail
Location of Repository

West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia.

By B Dieye, M Affara, L Sangare, F Joof, YD Ndiaye, JF Gomis, M Ndiaye, A Mbaye, M Diakite, N Sy, B Mbengue, AB Deme, R Daniels, AD Ahouidi, T Dieye, A Abdullahi, S Doumbia, JL Ndiaye, A Diarra, A Ismaela, M Coulibaly, C Welty, AA Ngwa, J Shaffer, U D'Alessandro, SK Volkman, DF Wirth, DJ Krogstad, O Koita, D Nwakanma and D Ndiaye


In 2006, artemether-lumefantrine (AL) became the first-line treatment of uncomplicated malaria in Senegal, Mali, and the Gambia. To monitor its efficacy, between August 2011 and November 2014, children with uncomplicated Plasmodium falciparum malaria were treated with AL and followed up for 42 days. A total of 463 subjects were enrolled in three sites (246 in Senegal, 97 in Mali, and 120 in Gambia). No early treatment failure was observed and malaria infection cleared in all patients by day 3. Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) was 100% in Mali, and the Gambia, and 98.8% in Senegal. However, without PCR adjustment, ACPR was 89.4% overall; 91.5% in Mali, 98.8% in Senegal, and 64.3% in the Gambia (the lower value in the Gambia attributed to poor compliance of the full antimalarial course). However, pfmdr1 mutations were prevalent in Senegal and a decrease in parasite sensitivity to artesunate and lumefantrine (as measured by ex vivo drug assay) was observed at all sites. Recrudescent parasites did not show Kelch 13 (K13) mutations and AL remains highly efficacious in these west African sites

Publisher: American Society of Tropical Medicine and Hygiene
Year: 2016
OAI identifier:
Provided by: LSHTM Research Online

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.